Details of the Drug Pharmacogenomic Perturbation Atlas

R547 Drug Info

LIA; R-547; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone

Cross-matching ID

PubChem CID

6918852

ChEBI ID

CHEMBL384304

CAS Number

CAS 741713-40-6

TTD Drug ID

D04FHB

General Information of Drug (ID: DMK25FU)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Complement and coagulation cascades	2.37	0.00e+0	76/85 (89.41%)	PLAT;CFB;C3;...
Viral protein interaction with cytokine and cytokine re...	2.29	0.00e+0	84/100 (84%)	CCL20;CXCL10;ACKR3;...
Rheumatoid arthritis	2.26	0.00e+0	78/93 (83.87%)	CCL20;CXCL8;CCL2;...
Fructose and mannose metabolism	2.13	3.63e-3	30/33 (90.91%)	SORD;PFKL;PFKM;...
Type I diabetes mellitus	2.07	2.91e-3	38/43 (88.37%)	CPE;IL1B;IL1A;...
Glycolysis / Gluconeogenesis	2.07	2.42e-3	56/67 (83.58%)	PFKL;PGM1;AKR1A1;...
Valine, leucine and isoleucine degradation	2.06	2.08e-3	42/48 (87.5%)	ACAA1;ACAT1;PCCB;...
Fatty acid degradation	2.06	1.82e-3	40/43 (93.02%)	ACAA1;ACAT1;HADHA;...
Pentose phosphate pathway	2.05	1.61e-3	25/30 (83.33%)	PFKL;PGM1;GPI;...
Tryptophan metabolism	2.04	1.45e-3	35/42 (83.33%)	KYNU;ACAT1;MAOA;...
ECM-receptor interaction	2.03	1.32e-3	80/88 (90.91%)	COL4A5;LAMC2;ITGAV;...
Focal adhesion	1.97	1.21e-3	180/201 (89.55%)	COL4A5;LAMC2;ITGAV;...
AGE-RAGE signaling pathway in diabetic complications	1.95	1.12e-3	97/100 (97%)	EGR1;CXCL8;COL4A5;...
Butanoate metabolism	1.94	1.04e-3	23/28 (82.14%)	ACAT1;HADHA;HMGCS2;...
Coronavirus disease	1.94	9.69e-4	215/232 (92.67%)	CFB;C3;ISG15;...
Oxidative phosphorylation	1.94	9.08e-4	93/133 (69.92%)	ATP6V0E2;NDUFS8;ATP6AP1;...
Tyrosine metabolism	1.94	8.55e-4	30/36 (83.33%)	MAOA;FAH;ADH1B;...
Other glycan degradation	1.93	1.61e-3	13/18 (72.22%)	MAN2B1;MAN2C1;HEXA;...
Graft-versus-host disease	1.93	1.53e-3	32/42 (76.19%)	IL1B;IL1A;HLA-DRB1;...
Allograft rejection	1.90	2.18e-3	32/38 (84.21%)	HLA-DRB1;HLA-DRA;HLA-DQA1;...
Pentose and glucuronate interconversions	1.88	2.08e-3	17/34 (50%)	SORD;UGT2B28;AKR1A1;...
Cytokine-cytokine receptor interaction	1.87	1.98e-3	246/295 (83.39%)	CCL20;CXCL10;ACKR3;...
Metabolism of xenobiotics by cytochrome P450	1.87	1.89e-3	49/77 (63.64%)	GSTM3;UGT2B28;ADH1B;...
Malaria	1.87	1.82e-3	44/50 (88%)	CXCL8;CCL2;IL1B;...
Retinol metabolism	1.87	1.74e-3	41/68 (60.29%)	UGT2B28;ADH1B;UGT2B15;...
Vitamin digestion and absorption	1.86	1.68e-3	17/24 (70.83%)	SCARB1;ABCC1;APOA1;...
Fat digestion and absorption	1.86	1.61e-3	35/43 (81.4%)	PLA2G2A;ACAT1;SCARB1;...
Leishmaniasis	1.84	1.56e-3	67/77 (87.01%)	C3;EEF1A2;IL1B;...
African trypanosomiasis	1.83	1.50e-3	32/37 (86.49%)	F2RL1;IL1B;HBB;...
beta-Alanine metabolism	1.81	4.36e-3	25/30 (83.33%)	HADHA;AOC3;CNDP2;...
Non-homologous end-joining	-1.61	4.59e-2	11/13 (84.62%)	NHEJ1;DNTT;FEN1
MicroRNAs in cancer	-1.62	4.21e-2	146/310 (47.1%)	FSCN1;HDAC5;HRAS;...
Homologous recombination	-1.69	2.68e-2	35/41 (85.37%)	POLD2;RPA2;RAD51B;...
Nucleotide excision repair	-1.76	1.40e-2	40/47 (85.11%)	RFC2;POLD3;RFC5;...
FoxO signaling pathway	-1.77	1.44e-2	118/131 (90.08%)	CDK2;FOXG1;NLK;...
Fanconi anemia pathway	-1.88	6.93e-3	36/54 (66.67%)	FANCC;TOP3A;RAD51C;...
mRNA surveillance pathway	-1.89	7.20e-3	71/98 (72.45%)	PPP2R1B;ACIN1;CPSF7;...
Mismatch repair	-1.93	4.11e-3	22/23 (95.65%)	RFC2;POLD3;RFC5;...
Base excision repair	-1.97	1.60e-3	29/33 (87.88%)	POLD3;POLE;LIG1;...
Spliceosome	-2.10	0.00e+0	101/150 (67.33%)	SNRPD2;LSM8;LSM7;...
Oocyte meiosis	-2.13	0.00e+0	90/129 (69.77%)	CDC23;PPP2CB;ITPR2;...
Progesterone-mediated oocyte maturation	-2.18	0.00e+0	75/100 (75%)	CDC23;PKMYT1;CDK2;...
DNA replication	-2.62	0.00e+0	34/36 (94.44%)	RFC2;POLD3;RFC5;...
Cell cycle	-2.75	0.00e+0	110/124 (88.71%)	ORC3;CDC23;E2F1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Ewing sarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
SK-ES-1	CVCL_0627	Homo sapiens	0.12uM - 10uM	24H

TC-32	CVCL_7141	Homo sapiens	0.12uM - 1.11uM	24H

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	0.12uM - 10uM	6H, 24H, 48H

Bone marrow

Chronic myeloid leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
HAP1	CVCL_Y019	Homo sapiens	0.66uM - 3.33uM	24H

HAP1 BRD4 (-) 1	CVCL_SF59	Homo sapiens	0.66uM - 3.33uM	24H

HAP1 CDK4 (-) 1	CVCL_SI36	Homo sapiens	0.66uM - 3.33uM	24H

HAP1 HDAC5 (-) 1	CVCL_SR11	Homo sapiens	0.66uM - 3.33uM	24H

HAP1 ITGA4 (-) 1	CVCL_ST27	Homo sapiens	0.66uM - 3.33uM	24H

HAP1 MAPK8 (-) 1	CVCL_SW99	Homo sapiens	0.66uM - 3.33uM	24H

HAP1 PIK3CA (-) 1	CVCL_TD60	Homo sapiens	0.66uM - 3.33uM	24H

HAP1 PRKACA (-) 1	CVCL_TG70	Homo sapiens	0.66uM - 3.33uM	24H

HAP1 PRKCQ (-)	CVCL_TG92	Homo sapiens	0.66uM - 3.33uM	24H

HAP1 RELA (-) 1	CVCL_TI75	Homo sapiens	0.66uM - 3.33uM	24H

HAP1 SRC (-) 1	CVCL_TQ36	Homo sapiens	0.66uM - 3.33uM	24H

HAP1 TP53 (-) 1	CVCL_RJ70	Homo sapiens	0.66uM - 3.33uM	24H

Brain

Glioblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
U-251 MG	CVCL_0021	Homo sapiens	0.12uM - 10uM	24H

YH-13	CVCL_1800	Homo sapiens	0.12uM - 10uM	24H

Glioma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
GI-1	CVCL_1230	Homo sapiens	0.12uM	24H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H, 48H

MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H

MDA-MB-468	CVCL_0419	Homo sapiens	0.12uM	24H

Breast ductal carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
BT-474	CVCL_0179	Homo sapiens	0.12uM - 10uM	24H

T-47D	CVCL_0553	Homo sapiens	0.12uM	24H

ZR-75-1	CVCL_0588	Homo sapiens	0.12uM - 10uM	24H

Fibrocystic breast disease

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A (Parent)	CVCL_0598	Homo sapiens	1.11uM - 10uM	3H, 6H, 12H, 24H

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
GP2d	CVCL_1234	Homo sapiens	0.12uM - 1.11uM	24H

HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H

SNU-407	CVCL_5004	Homo sapiens	0.12uM - 10uM	24H

Embryonic stem cell

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
WA09 (H9) Derived	CVCL_9773 (WA09)	Homo sapiens	0.12uM - 10uM	24H

Endometrium

Endometrial adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
HEC-108	CVCL_2926	Homo sapiens	0.12uM - 10uM	24H

HEC-151	CVCL_2927	Homo sapiens	0.12uM - 10uM	24H

HEC-1-A	CVCL_0293	Homo sapiens	0.12uM - 10uM	24H

HEC-251	CVCL_2928	Homo sapiens	0.12uM - 1.11uM	24H

HEC-265	CVCL_2929	Homo sapiens	0.12uM - 10uM	24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
CJM	CVCL_U797	Homo sapiens	0.12uM - 1.11uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 3.33uM	24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Renal cell carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
RCC10RGB	CVCL_1656	Homo sapiens	0.12uM - 1.11uM	24H

Rhabdoid tumor

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
G-401	CVCL_0270	Homo sapiens	0.12uM - 1.11uM	24H

Liver

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
JHH-5	CVCL_1320	Homo sapiens	0.12uM	24H

JHH-7	CVCL_1322	Homo sapiens	0.12uM - 10uM	24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H, 48H

NCI-H1437	CVCL_1472	Homo sapiens	0.12uM - 1.11uM	24H

NCI-H1573	CVCL_1483	Homo sapiens	0.12uM	24H

NCI-H838	CVCL_1594	Homo sapiens	0.12uM - 10uM	24H

Lung squamous cell carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
BEN	CVCL_1081	Homo sapiens	0.12uM - 1.11uM	24H

HCC1588	CVCL_1263	Homo sapiens	0.12uM - 1.11uM	24H

HCC95	CVCL_1276	Homo sapiens	1.11uM - 10uM	24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
NCI-H2110	CVCL_1529	Homo sapiens	0.12uM - 10uM	24H

NCI-H2172	CVCL_1534	Homo sapiens	0.12uM - 10uM	24H

Small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
NCI-H841	CVCL_1595	Homo sapiens	0.12uM - 10uM	24H

Muscle

Rhabdomyosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-204	CVCL_0134	Homo sapiens	0.12uM	24H

Oral cavity

Oral squamous cell carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
BICR 6	CVCL_1086	Homo sapiens	0.12uM - 1.11uM	24H

Ovary

Ovarian carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
OVK18	CVCL_1629	Homo sapiens	0.12uM - 10uM	24H

Ovarian clear cell carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
ES-2	CVCL_3509	Homo sapiens	0.12uM - 10uM	24H

OVTOKO	CVCL_3114	Homo sapiens	0.12uM - 10uM	24H

Ovarian cystadenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
OAW 28	CVCL_1611	Homo sapiens	0.12uM - 10uM	24H

OC 316	CVCL_1615	Homo sapiens	0.12uM - 10uM	24H

Ovarian endometrioid carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
TOV-112D	CVCL_3612	Homo sapiens	0.12uM - 1.11uM	24H

Ovarian granulosa cell tumor

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
COV434	CVCL_2010	Homo sapiens	0.12uM - 1.11uM	24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 2.22uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 2.22uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 3.33uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
22Rv1	CVCL_1045	Homo sapiens	0.12uM - 10uM	24H

LNCaP clone FGC	CVCL_1379	Homo sapiens	0.12uM - 10uM	24H

PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H

IGR-37	CVCL_1303	Homo sapiens	0.12uM - 1.11uM	24H

Mel-HO	CVCL_1402	Homo sapiens	0.12uM	24H

SH-4	CVCL_1692	Homo sapiens	0.12uM	24H

SK-MEL-3	CVCL_0525	Homo sapiens	0.12uM - 10uM	24H

Stomach

Gastric adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
AGS	CVCL_0139	Homo sapiens	0.12uM - 10uM	24H

MKN45	CVCL_0434	Homo sapiens	0.12uM - 10uM	24H

Gastric carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
IM95	CVCL_1305	Homo sapiens	0.12uM - 10uM	24H

Urinary bladder

Bladder carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
BC-3C	CVCL_1079	Homo sapiens	0.12uM - 1.11uM	24H

Bladder transitional cell carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
CAL-29	CVCL_1109	Homo sapiens	0.12uM	24H